Open AccessS280: B‐CELL MALIGNANCIES TREATED WITH TARGETED DRUGS AND SARS‐COV‐2 INFECTION. A EUROPEAN HEMATOLOGY ASSOCIATION SURVEY (EPICOVIDEHA)
Author(s) -
Infante M. S.,
SalmantonGarcía J.,
FernandezCruz A.,
Marchesi F.,
RÁČIL Z.,
Hanakova M.,
Jaksic O.,
Weinbergerova B.,
Besson C.,
Duarte R.,
Itri F.,
VALKOVIĆ T.,
Busca A.,
Guidetti A.,
GLENTHØJ A.,
Collins G.,
Bonuomo V.,
Sili U.,
Seval G.,
Machado M.,
LopezGarcia A.,
Cordoba R.,
Blennow O.,
Abuzeinah G.,
Lemure S.,
Kulasekararaj A.,
FalcesRomero I.,
Cattaneo C.,
Cornely O. A.,
HernandezRivas J.A.,
Pagano L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844012.13018.0a
Subject(s) - medicine , lenalidomide , ibrutinib , idelalisib , ofatumumab , rituximab , oncology , pembrolizumab , nivolumab , cetuximab , lymphoma , brentuximab vedotin , immunology , cancer , multiple myeloma , chronic lymphocytic leukemia , hodgkin lymphoma , leukemia , immunotherapy , colorectal cancer